Oncology Institute (TOI) Stock Forecast, Price Target & Predictions
TOI Stock Forecast
Oncology Institute stock forecast is as follows: an average price target of $8.00 (represents a 2757.14% upside from TOI’s last price of $0.28) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
TOI Price Target
The average price target for Oncology Institute (TOI) is $8.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $6.00. This represents a potential 2757.14% upside from TOI's last price of $0.28.
TOI Analyst Ratings
According to 2 Wall Street analysts, Oncology Institute's rating consensus is 'Buy'. The analyst rating breakdown for TOI stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Oncology Institute Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 11, 2022 | - | Guggenheim | $6.00 | $2.50 | 140.10% | 2042.86% |
| Aug 15, 2022 | - | Jefferies | $10.00 | $6.44 | 55.28% | 3471.43% |
The latest Oncology Institute stock forecast, released on Nov 11, 2022 by Guggenheim company, set a price target of $6.00, which represents a 140.10% increase from the stock price at the time of the forecast ($2.50), and a 2042.86% increase from TOI last price ($0.28).
Oncology Institute Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.28 | $0.28 | $0.28 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Oncology Institute stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Oncology Institute's last price of $0.28. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 11, 2022 | Guggenheim | Buy | Buy | Hold |
| Aug 15, 2022 | Jefferies | - | Buy | Initialise |
Oncology Institute's last stock rating was published by Guggenheim on Nov 11, 2022. The company gave TOI a "Buy" rating, the same as its previous rate.
Oncology Institute Financial Forecast
Oncology Institute Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | $85.79M | $82.03M | $80.22M | $76.19M | $71.42M | $64.98M |
| Avg Forecast | $109.15M | $107.54M | $103.31M | $95.17M | $82.04M | $74.66M | $73.80M | $65.00M | $64.73M | $68.95M |
| High Forecast | $109.15M | $107.54M | $103.31M | $95.17M | $82.04M | $74.66M | $73.80M | $65.00M | $64.73M | $68.95M |
| Low Forecast | $109.15M | $107.54M | $103.31M | $95.17M | $82.04M | $74.66M | $73.80M | $65.00M | $64.73M | $68.95M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | 1.05% | 1.10% | 1.09% | 1.17% | 1.10% | 0.94% |
Oncology Institute's average Quarter revenue forecast for Mar 24 based on 1 analysts is $95.17M, with a low forecast of $95.17M, and a high forecast of $95.17M. TOI's average Quarter revenue forecast represents a 10.93% increase compared to the company's last Quarter revenue of $85.79M (Dec 23).
Oncology Institute EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | $-15.15M | $-13.16M | $-12.99M | $-13.38M | $-13.27M | $-19.00M |
| Avg Forecast | $-15.18M | $-14.96M | $-14.37M | $-13.23M | $-11.41M | $-10.38M | $-10.26M | $-9.04M | $-9.00M | $-9.59M |
| High Forecast | $-15.18M | $-14.96M | $-14.37M | $-13.23M | $-11.41M | $-10.38M | $-10.26M | $-9.04M | $-9.00M | $-9.59M |
| Low Forecast | $-15.18M | $-14.96M | $-14.37M | $-13.23M | $-11.41M | $-10.38M | $-10.26M | $-9.04M | $-9.00M | $-9.59M |
| Surprise % | - | - | - | - | 1.33% | 1.27% | 1.27% | 1.48% | 1.47% | 1.98% |
undefined analysts predict TOI's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Oncology Institute's previous annual EBITDA (undefined) of $NaN.
Oncology Institute Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | $-18.75M | $-17.42M | $-16.90M | $-30.00M | $-9.50M | $-2.67M |
| Avg Forecast | $-5.98M | $-5.23M | $-6.73M | $-8.97M | $-8.22M | $-9.72M | $-12.71M | $-12.71M | $-14.95M | $-13.45M |
| High Forecast | $-5.98M | $-5.23M | $-6.73M | $-8.97M | $-8.22M | $-9.72M | $-12.71M | $-12.71M | $-14.95M | $-13.45M |
| Low Forecast | $-5.98M | $-5.23M | $-6.73M | $-8.97M | $-8.22M | $-9.72M | $-12.71M | $-12.71M | $-14.95M | $-13.45M |
| Surprise % | - | - | - | - | 2.28% | 1.79% | 1.33% | 2.36% | 0.64% | 0.20% |
Oncology Institute's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TOI's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Oncology Institute SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | $28.09M | $28.20M | $28.73M | $28.83M | $29.57M | $31.96M |
| Avg Forecast | $36.01M | $35.48M | $34.08M | $31.40M | $27.07M | $24.63M | $24.35M | $21.45M | $21.36M | $22.75M |
| High Forecast | $36.01M | $35.48M | $34.08M | $31.40M | $27.07M | $24.63M | $24.35M | $21.45M | $21.36M | $22.75M |
| Low Forecast | $36.01M | $35.48M | $34.08M | $31.40M | $27.07M | $24.63M | $24.35M | $21.45M | $21.36M | $22.75M |
| Surprise % | - | - | - | - | 1.04% | 1.14% | 1.18% | 1.34% | 1.38% | 1.40% |
Oncology Institute's average Quarter SG&A projection for Mar 24 is $31.40M, based on 1 Wall Street analysts, with a range of $31.40M to $31.40M. The forecast indicates a 11.78% rise compared to TOI last annual SG&A of $28.09M (Dec 23).
Oncology Institute EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | $-0.26 | $-0.24 | $-0.00 | $-0.41 | $-0.13 | $-0.04 |
| Avg Forecast | $-0.08 | $-0.07 | $-0.09 | $-0.12 | $-0.11 | $-0.13 | $-0.17 | $-0.17 | $-0.20 | $-0.18 |
| High Forecast | $-0.08 | $-0.07 | $-0.09 | $-0.12 | $-0.11 | $-0.13 | $-0.17 | $-0.17 | $-0.20 | $-0.18 |
| Low Forecast | $-0.08 | $-0.07 | $-0.09 | $-0.12 | $-0.11 | $-0.13 | $-0.17 | $-0.17 | $-0.20 | $-0.18 |
| Surprise % | - | - | - | - | 2.36% | 1.85% | 0.00% | 2.41% | 0.65% | 0.21% |
According to undefined Wall Street analysts, Oncology Institute's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TOI previous annual EPS of $NaN (undefined).
Oncology Institute Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| TOI | Oncology Institute | $0.28 | $8.00 | 2757.14% | Buy |
| CANO | Cano Health | $2.30 | $6.42 | 179.13% | Buy |
| JYNT | Joint | $11.10 | $20.00 | 80.18% | Buy |
| AGL | agilon health | $2.67 | $4.40 | 64.79% | Buy |
| SGRY | Surgery Partners | $29.22 | $44.33 | 51.71% | Buy |
| BKD | Brookdale Senior Living | $6.24 | $7.50 | 20.19% | Buy |
| MD | Pediatrix Medical Group | $15.14 | $18.17 | 20.01% | Hold |
| SEM | Select Medical | $36.51 | $40.00 | 9.56% | Buy |
| PNTG | Pennant Group | $32.38 | $34.67 | 7.07% | Buy |
| ADUS | Addus HomeCare | $128.96 | $129.40 | 0.34% | Buy |
| UHS | Universal Health Services | $208.83 | $208.47 | -0.17% | Hold |
| EHC | Encompass Health | $100.23 | $97.00 | -3.22% | Buy |
| ENSG | Ensign Group | $153.39 | $148.20 | -3.38% | Buy |
| SNDA | Sonida Senior Living | $25.24 | $13.00 | -48.49% | Sell |
TOI Forecast FAQ
Is Oncology Institute a good buy?
Yes, according to 2 Wall Street analysts, Oncology Institute (TOI) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of TOI's total ratings.
What is TOI's price target?
Oncology Institute (TOI) average price target is $8 with a range of $6 to $10, implying a 2757.14% from its last price of $0.28. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Oncology Institute stock go up soon?
According to Wall Street analysts' prediction for TOI stock, the company can go up by 2757.14% (from the last price of $0.28 to the average price target of $8), up by 3471.43% based on the highest stock price target, and up by 2042.86% based on the lowest stock price target.
Can Oncology Institute stock reach $0?
TOI's average twelve months analyst stock price target of $8 supports the claim that Oncology Institute can reach $0 in the near future.
What are Oncology Institute's analysts' financial forecasts?
TOI's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $415.16M (high $415.16M, low $415.16M), average EBITDA is $-57.733M (high $-57.733M, low $-57.733M), average net income is $-26.909M (high $-26.909M, low $-26.909M), average SG&A $136.98M (high $136.98M, low $136.98M), and average EPS is $-0.36 (high $-0.36, low $-0.36).
Did the TOI's actual financial results beat the analysts' financial forecasts?
Based on Oncology Institute's last annual report (Dec 2023), the company's revenue was $324.24M, beating the average analysts forecast of $295.51M by 9.72%. Apple's EBITDA was $-70.382M, beating the average prediction of $-41.094M by 71.27%. The company's net income was $-83.068M, beating the average estimation of $-43.354M by 91.60%. Apple's SG&A was $113.85M, beating the average forecast of $97.5M by 16.77%. Lastly, the company's EPS was $-1.13, beating the average prediction of $-0.58 by 94.83%. In terms of the last quarterly report (Dec 2023), Oncology Institute's revenue was $85.79M, beating the average analysts' forecast of $82.04M by 4.57%. The company's EBITDA was $-15.149M, beating the average prediction of $-11.409M by 32.78%. Oncology Institute's net income was $-18.754M, beating the average estimation of $-8.222M by 128.09%. The company's SG&A was $28.09M, beating the average forecast of $27.07M by 3.77%. Lastly, the company's EPS was $-0.26, beating the average prediction of $-0.11 by 136.36%